Stallergenes Greer Ltd

Just a month after expressing “substantial doubt regarding its ability to continue as a going concern,” DBV Technologies shares are soaring on the news that the French firm has reached agreement with

The US Food and Drug Administration’s vaccines advisory committee now will handle allergenic products following the termination of a panel created 40 years ago to deal with the rarely seen application

The news that Novartis AG has terminated a late-stage peanut allergy trial of one of its more closely watched assets, ligelizumab, looks like good news for other players in the space, notably DBV T

Three years after inking a $2.6bn deal to acquire Aimmune Therapeutics, Inc. , Nestlé has finally thrown in the towel on the therapy at the centre of that purchase, the peanut allergy treatment Pal